Delivery Order SPE2DB22D1103-SPE2DB25FTNR4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector units valued at $1,304.29 under a firm fixed price contract. This non-set-aside delivery order, which is scheduled for completion by September 5, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of September 15, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the vendor performing the work at its corporate office location in the same municipality. This delivery order is issued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,678.14 for Xyosted 75 mg/0.5 mL auto-injector supplies on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price, non-set-aside delivery order will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order valued at $1,152.52 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies, with an ultimate completion date of April 25, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for military and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,901.27 on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector vials. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 4, 2025. This delivery order operates as a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,090.66 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xyosted 50 mg/0.5 mL auto-injector cartridges. The contract is a firm fixed price delivery order with an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was made without a set-aside designation, indicating competitive selection among qualified...
- This delivery order, awarded July 28, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides Xyosted 100 mg/0.5 mL auto-injector pharmaceutical supplies with a ceiling value of $1,092.55. The contract utilizes firm fixed pricing and is scheduled for completion by July 29, 2025. As a non-set-aside, competitively awarded delivery order, this award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,936.96 delivery order on July 23, 2025, for XYOSTED 75 mg/0.5 mL auto-injector units (0.5 mL). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger pharmaceutical supply...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,188.98 on July 22, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 23, 2025, and performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTNR4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector prefilled syringes, valued at $1,207.05. This firm fixed-price delivery order represents a non-set-aside award and is scheduled for completion by June 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement serving military and veteran healthcare systems. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order reflects AmerisourceBergen's role as a primary pharmaceutical supplier within the DLA's global medical supply chain. Xyosted is a testosterone replacement therapy product delivered via auto-injector, representing the type of specialty pharmaceutical product the contractor regularly supplies to support military healthcare programs worldwide. This competitively awarded transaction exemplifies the contractor's demonstrated capability to fulfill federal medical supply requirements across therapeutic domains through the DLA's comprehensive pharmaceutical prime vendor vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 6/2/25 |